Clinical trial readout dates for ImmunityBio Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is March 2027.
| Phase 2 Anktiva Long COVID; Long COVID Syndrome · NCT07123727 | March 2027 Recruiting |
| Phase 2 Gemcitabine Platinum-resistant Ovarian Cancer · NCT06710288 | May 2027 Recruiting |
| Phase 2 CD19 t-haNK- IV Administration Relapsed B-Cell Non Hodgkin Lymphoma · NCT07125872 | May 2027 Recruiting |
| Phase 2 Nogapendekin alfa inbakicept (NAI) Sepsis; Septic Shock · NCT07578558 | August 2027 Not Yet Recruiting |
| Phase 2 CD19 t-haNK- IV Administration Relapsed B-Cell Non-Hodgkin Lymphoma · NCT07477366 | December 2027 Not Yet Recruiting |
| Phase 1/2 Intravesical Recombinant Mycobacterium (rMBCG) NMIBC · NCT06800963 | February 2028 Recruiting |
| Phase 2 Nogapendekin alfa inbakicept (NAI) Sepsis · NCT07783789 | May 2028 Not Yet Recruiting |
| Phase 3 N-803 NSCLC Stage IV · NCT06745908 | September 2028 Recruiting |
| Phase 2 N-803 + Pembrolizumab Non-Small Cell Lung Cancer; Small Cell Lung Cancer · NCT03228667 | August 2029 Ongoing |
These dates have elapsed; the company may have reported, or guidance may have shifted.
| Phase 2 N-803 and BCG Non-muscle Invasive Bladder Cancer (NMIBC) · NCT06829823 | November 2026 Not Yet Recruiting |
ImmunityBio Inc. reported $334M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-09). Its net loss for that quarter was $185M; at that rate the cash would last about 2 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-09 |
| 8-K Reg FD Disclosure — often a data announcement | 2026-11-09 |